Kinoxis Therapeutics is a clinical stage biotechnology company developing compounds to restore normal social functioning by rebalancing activity in malfunctioning social pathways in the brain. The company focuses on treatments for social dysfunction and substance use disorders.

Kinoxis Therapeutics

Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney.  Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US National Institutes of Health National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.

Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and has completed a Phase I clinical study.  The company is also exploring other indications for KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.

Kinoxis’ second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder) social anxiety disorder, dementia (including Alzheimer’s disease), and schizophrenia.

National Institutes of Health

Uniseed Ventures

Stoic VC

Kinoxis Therapeutics Pty Ltd

Kinoxis Therapeutics Pty Ltd is pleased to announce the successful completion of a Series B round of capital raise. A total of $14.5 million funding has been raised through this round, led by key investors Uniseed, UniSuper, University of Sydney, Stoic Venture Capital, Avicella Capital, as well as a number of sophisticated investors.
 
The funds raised will be used to support Phase 2 programs for Kinoxis’ lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders.
 
One of the supported programs is CARES-X, a phase 2 clinical study commencing this month. First of its kind in Australia, CARES-X will be conducted across 8 sites with 60 patients, examining the safety, tolerability and efficacy of KNX100 when used as a treatment of agitation in dementia patients.
 
Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said:” “This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. This is a new and highly promising area of development for KNX100, and we are grateful to have had the strong support from our major investors.”
 
Thanks also to Lis Boyce at Piper Alderman and the team at Bio101 for their support through this round.
 
For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem

#AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment

Kinoxis Therapeutics Pty Ltd is pleased to share that our CEO, Hugh Alsop has been announced as the inaugural recipient of the CEO of the Year award at The Brooker Prize gala.
 
The CEO of the Year award recognises individuals who have made a significant commercial, educational, member-driven or research-based contribution to their organisation or the sector. Thank you Brooker Consulting for this prestigious acknowledgment of Hugh’s contribution to the biotech and life sciences industry. 

As seen in this photo: John Kurek, Investor Director at Uniseed and Dr Rachel C., Principal of Brooker Consulting with Kinoxis CEO, Hugh Alsop. 
 
#leadershipaward #biotech #lifesciences

Kinoxis Therapeutics Pty Ltd CEO Hugh Alsop presenting at #BIO2024 on our clinical stage programs exploring KNX100 for treating agitation and aggression in dementia and substance use disorders

Excited to the share the Kinoxis Therapeutics story at the BIO International Convention in San Diego next week. Join me for my presentation on Wednesday, June 5 at 4:00 PM in Company Presentation Theater 4. See you there. #BIO2024 Kinoxis Therapeutics Pty Ltd

I really enjoyed participating in the session on Alcohol and opioids: overdose, stress, and treatment this morning at the International Drug & Alcohol Research Society Meeting in Rio, where I spoke about the Kinoxis Therapeutics Pty Ltd program developing the clinical stage KNX100 compound for the treatment of substance use disorders.

I recently attended the College on Problems of Drug Dependence (CPDD) Conference in lovely Montreal, Canada. With drug overdoses claiming a life every five minutes in the US alone, the work of the CPDD organization is more critical than ever.

Key discussions at the conference included the importance of addressing polysubstance use and the urgent need for harm reduction strategies. Innovative therapies in development were also highlighted, along with a focused discussion on drug craving—a major factor in the cycle of substance use disorders and a key contributor to relapse. By effectively treating drug cravings, we could reduce the risk of relapse to drug taking. 

👩‍🔬 At Kinoxis Therapeutics Pty Ltd, we are making significant strides in the field of substance use disorders. 

#CPDD2024 #DrugDependence #SubstanceUseDisorders #AddictionResearch #Montreal #Biotech

msh id	COM:KINOXISTHERAPEUTICS
symbol	-
name	Kinoxis Therapeutics
homepage url	https://kinoxistherapeutics.com
country	AU
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	16
crunchbase url	-
linkedin url	https://www.linkedin.com/company/kinoxis-therapeutics-pty-ltd
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

KINO

COM:KINOXISTHERAPEUTICS

Kinoxis Therapeutics

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-